US Healthcare Providers Face Q2 Pressures Amid ACA Policy Shifts

The US healthcare services and managed care sector is facing acute profit margin pressures in the second quarter of 2026, driven by higher-than-expected losses from Affordable Care Act (ACA) policy shifts and broader market rotations out of defensive names, according to industry data and recent company filings.

Humana Inc (HUM.US)

Shares of Humana Inc (HUM.US) have seen recent volatility amid broader sector shifts. The company is nearing a deal to sell its minority stake in Gentiva, valued at roughly USD 900M, with proceeds earmarked for general corporate purposes. This transaction is targeted to close in the third quarter of 2026. Furthermore, Humana continues to expand its value-based care footprint, recently acquiring MaxHealth in Florida, bringing 82 clinics and 120,000 patients into its CenterWell network. BofA Securities raised its price target on the stock to USD 410 in July, citing steady operational momentum.

The Cigna Group (CI.US)

The Cigna Group (CI.US) saw its shares drop about 5% in mid-July, reflecting weak fund momentum for defensive healthcare stocks against a backdrop of broader tech-driven market selloffs. The health services firm, which appointed Brian Evanko as its new Chief Executive Officer on June 1, 2026, previously raised its full-year forecast following robust first-quarter results. The company is scheduled to report its second-quarter financials on July 30. Separately, The Cigna Group Foundation announced a USD 3M grant program aimed at supporting youth mental health initiatives.

HCA Healthcare Inc (HCA.US)

HCA Healthcare Inc (HCA.US) plunged over 6% intraday following a preliminary earnings release that severely slashed its full-year forecast. The hospital operator lowered its 2026 net income projection to a range of USD 6.3B to USD 6.7B. The company is now targeting more than USD 1B in losses this year due to an increase in uninsured patients tied to ACA coverage roll-offs, including a USD 400M hit recognized in the second quarter alone. Despite these headwinds, preliminary Q2 revenues are expected to top USD 20.2B, up from USD 18.6B a year earlier, according to the company.

The ongoing adjustments to ACA subsidies appear set to reshape the profit outlook across the broader hospital space, prompting analysts to aggressively revise their valuation models for the sector.

This article does not constitute investment advice.